Alcobra is a pharmaceutical company focused on the development of new medications to help patients with cognitive disorders including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome. Metadoxine Extended Release (MDX) is the company’s lead investigational product candidate.